Non-Metastatic Neoplasm Clinical Trial
Official title:
Impact of an Intervention Combining Self-care and Hypnosis on the Well-being of Cancer Patients and Their Partners
Hypnosis-based interventions are starting to be tested in order to improve emotional distress
and fatigue of cancer patients. However, most of these studies only include breast cancer
patients and do no measure long-term effects of such interventions.
Our randomized controlled trial aims to propose to 116 post-treatment cancer patients (all
tumour localisations accepted) an 8-week groupal intervention combining hypnosis and
self-care techniques.
Primary outcomes (emotion regulation, emotional distress, fatigue) and secondary outcomes
(sleep difficulties, fear of recurrence, attentional bias, conjugal communication) will be
investigated at 3 measurement times: before the intervention (T1), 3 months later (T2 - right
after the intervention of the experimental group, and right before the intervention of the
control group) and again 3 months later (T3 - after the intervention of the control group).
Some questionnaires, two relaxation tasks, an attentional task, an actigraph and a smartphone
application will be used to collect data. The indirect impact of the intervention on
participants' partners will also be measured by questionnaires (emotional distress, conjugal
communication).
Data collection has started on March 2017. Our results should bring new knowledge about the
efficacy of an hypnosis-based intervention to improve fatigue and well-being in cancer
patients, which are often under-diagnosed and under-treated, but also about the indirect
efficacy to improve partners' well-being. Those results might contribute to spread this kind
of inexpensive intervention in oncology settings.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT05943301 -
Study of the Impact of Non-pharmacological Techniques on Cognitive Complaints in Cancer Patients
|
N/A | |
| Recruiting |
NCT01280825 -
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
|